GlassScriptPhysician profile
Matthew Arnold Ramos Libiran
NPI 1588656995
$12,966.03
in general payments reported to CMS, 2019-2025
59 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $1,226 · 2021: $2,690 · 2022: $2,097 · 2023: $2,335 · 2024: $1,880 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,606.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,458.58 | 2019-2024 | Hetlioz, Fanapt |
| Abbvie INC. | $1,337.25 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,250.18 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $740.47 | 2019-2025 | |
| Amgen INC. | $704.22 | 2019-2025 | Tepezza, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $567.81 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $549.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $531.60 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sanofi-Aventis U.S. LLC | $507.77 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $459.58 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.42 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $329.58 | 2019-2023 | Xarelto, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.92 | 2021-2024 | Caplyta |
| Glaxosmithkline, LLC. | $253.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $250.81 | 2019-2020 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $245.01 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.45 | 2019-2025 | Tradjenta, Jardiance, Ofev |
| Indivior INC. | $201.58 | 2022-2024 | Perseris, Sublocade |
| Lilly USA, LLC | $173.78 | 2019-2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $165.90 | 2025 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $158.64 | 2020-2021 | |
| Astellas Pharma US INC | $138.33 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $131.88 | 2020-2021 | |
| Exact Sciences Corporation | $129.96 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $118.89 | 2021-2024 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $107.00 | 2019-2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $100.14 | 2022-2025 | Gvoke Hypopen |
| Alkermes, INC. | $98.19 | 2022-2024 | Aristada, Lybalvi |
| Phathom Pharmaceuticals, INC. | $94.99 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $94.14 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $93.58 | 2019-2021 | |
| Axsome Therapeutics, INC. | $84.76 | 2023 | Auvelity |
| Vifor Pharma, INC. | $80.98 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $70.96 | 2024-2025 | Isturisa, Signifor Lar |
| Sumitomo Pharma America, INC. | $69.83 | 2023-2025 | Gemtesa |
| Endo Pharmaceuticals INC. | $66.79 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.65 | 2022 | |
| Abbott Laboratories | $56.50 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $47.14 | 2019-2023 | Trintellix |
| Gilead Sciences, INC. | $40.11 | 2019 | |
| Corium, LLC | $37.24 | 2023-2024 | Adlarity, Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $36.82 | 2021-2025 | |
| Corcept Therapeutics | $35.58 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $35.50 | 2022-2023 | Quviviq |
| Shire North American Group INC | $32.71 | 2019 | |
| Avanir Pharmaceuticals, INC. | $32.05 | 2019-2020 | |
| Noven Therapeutics, LLC | $29.90 | 2021-2022 | |
| Madrigal Pharmaceuticals | $28.70 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $25.62 | 2025 | Yorvipath |
| Organon LLC | $24.63 | 2022 | |
| Baxter Healthcare | $21.25 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Alvogen INC | $19.54 | 2025 | Teriparatide |
| Cequr Corporation | $17.43 | 2023 | Cequr Simplicity |
| Shield Therapeutics INC | $16.38 | 2024 | |
| Genentech USA, INC. | $14.68 | 2021 | |
| Sanofi Pasteur INC. | $13.75 | 2023 | |
| Amneal Pharmaceuticals LLC | $13.17 | 2024 | Unithroid |
| Adlon Therapeutics L.P. | $12.86 | 2019 | |
| Exeltis, USA INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Libiran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.